Alemtuzumab Treatment
Alemtuzumab is a monoclonal antibody therapy used in the treatment of B-cell lymphoma, a type of cancer in the lymphatic system. It is administered via infusion and works by targeting a molecule called CD52 which is present on the surface of B-cells. By binding to the CD52 molecule, alemtuzumab induces the death of B-cells and reduces the number and activity of cancerous cells. This therapy has been found to be effective in improving the prognosis in patients with follicular lymphoma and chronic lymphocytic leukemia and is being investigated for use in other types of cancer. It is generally well tolerated and provides an alternative treatment option for patients who cannot receive standard chemotherapy.
← International Journal of Multiple Sclerosis and Related Disorders